Roth Capital Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces $37 Price Target

Roth Capital analyst Yasmeen Rahimi initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating and a $37 price target.

Benzinga · 12/23/2019 15:52

Roth Capital analyst Yasmeen Rahimi initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating and a $37 price target.